{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:30:01Z","timestamp":1783161001619,"version":"3.54.6"},"reference-count":387,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Tuberkulose ist in Deutschland eine seltene, \u00fcberwiegend gut behandelbare Erkrankung. Weltweit ist sie eine der h\u00e4ufigsten Infektionserkrankungen mit ca. 10 Millionen Neuerkrankungen\/Jahr. Auch bei einer niedrigen Inzidenz in Deutschland bleibt Tuberkulose insbesondere aufgrund der internationalen Entwicklungen und Migrationsbewegungen eine wichtige Differenzialdiagnose. In Deutschland besteht, aufgrund der niedrigen Pr\u00e4valenz der Erkrankung und der damit verbundenen abnehmenden klinischen Erfahrung, ein Informationsbedarf zu allen Aspekten der Tuberkulose und ihrer Kontrolle. Diese Leitlinie umfasst die mikrobiologische Diagnostik, die Grundprinzipien der Standardtherapie, die Behandlung verschiedener Organmanifestationen, den Umgang mit typischen unerw\u00fcnschten Arzneimittelwirkungen, die Besonderheiten in der Diagnostik und Therapie resistenter Tuberkulose sowie die Behandlung bei TB-HIV-Koinfektion. Sie geht dar\u00fcber hinaus auf Versorgungsaspekte und gesetzliche Regelungen wie auch auf die Diagnosestellung und pr\u00e4ventive Therapie einer latenten tuberkul\u00f6sen Infektion ein. Es wird ausgef\u00fchrt, wann es der Behandlung durch spezialisierte Zentren bedarf.<\/jats:p><jats:p>Die Aktualisierung der S2k-Leitlinie \u201eTuberkulose im Erwachsenenalter\u201c soll allen in der Tuberkuloseversorgung T\u00e4tigen als Richtschnur f\u00fcr die Pr\u00e4vention, die Diagnose und die Therapie der Tuberkulose dienen und helfen, den heutigen Herausforderungen im Umgang mit Tuberkulose in Deutschland gewachsen zu sein.<\/jats:p>","DOI":"10.1055\/a-1934-8303","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:11:13Z","timestamp":1668643873000},"page":"727-819","source":"Crossref","is-referenced-by-count":36,"title":["Tuberkulose im Erwachsenenalter"],"prefix":"10.1055","volume":"76","author":[{"given":"Tom","family":"Schaberg","sequence":"additional","affiliation":[{"name":"Deutsches Zentralkomitee zur Bek\u00e4mpfung der Tuberkulose e.\u200aV. (DZK), Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folke","family":"Brinkmann","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr p\u00e4diatrische Pneumologie\/CF-Zentrum, Universit\u00e4tskinderklinik der Ruhr-Universit\u00e4t Bochum, Bochum"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Feiterna-Sperling","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr P\u00e4diatrie mit Schwerpunkt Pneumologie, Immunologie und Intensivmedizin, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin und Humboldt-Universit\u00e4t zu Berlin, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilte","family":"Geerdes-Fenge","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Innere Medizin, Universit\u00e4tsmedizin Rostock"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Labor Dr. Wisplinghoff K\u00f6ln, Klinische Infektiologie, K\u00f6ln"},{"name":"Department f\u00fcr Klinische Infektiologie, St. Vinzenz-Hospital, K\u00f6ln"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"H\u00e4cker","sequence":"additional","affiliation":[{"name":"Deutsches Zentralkomitee zur Bek\u00e4mpfung der Tuberkulose e.\u200aV. (DZK), Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hauer","sequence":"additional","affiliation":[{"name":"Robert Koch-Institut, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Haas","sequence":"additional","affiliation":[{"name":"Robert Koch-Institut, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Heyckendorf","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin I, Universit\u00e4tsklinikum Schleswig-Holstein, Campus Kiel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[{"name":"Klinische Infektiologie, Forschungszentrum Borstel"},{"name":"Deutsches Zentrum f\u00fcr Infektionsforschung (DZIF), Standort Hamburg-L\u00fcbeck-Borstel-Riems"},{"name":"Respiratory Medicine and International Health, Universit\u00e4t zu L\u00fcbeck, L\u00fcbeck"},{"name":"Baylor College of Medicine and Texas Children\u02bcs Hospital, Global TB Program, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian P.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Nationales Referenzzentrum f\u00fcr Mykobakterien, Forschungszentrum Borstel, Borstel"},{"name":"Institut f\u00fcr Medizinische Mikrobiologie, Virologie und Hygiene, Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Nienhaus","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP), Universit\u00e4tsklinikum Hamburg Eppendorf (UKE), Hamburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Otto-Knapp","sequence":"additional","affiliation":[{"name":"Deutsches Zentralkomitee zur Bek\u00e4mpfung der Tuberkulose e.\u200aV. (DZK), Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Priwitzer","sequence":"additional","affiliation":[{"name":"Gesundheitsamt, Landeshauptstadt Stuttgart"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Richter","sequence":"additional","affiliation":[{"name":"MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut J.F.","family":"Salzer","sequence":"additional","affiliation":[{"name":"Kepler Universit\u00e4tsklinikum, Linz, \u00d6sterreich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Schoch","sequence":"additional","affiliation":[{"name":"Kantonsspital St. Gallen, Schweiz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sch\u00f6nfeld","sequence":"additional","affiliation":[{"name":"Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Stahlmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr klinische Pharmakologie und Toxikologie, Charit\u00e9 Universit\u00e4tsmedizin, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Bauer","sequence":"additional","affiliation":[{"name":"Deutsches Zentralkomitee zur Bek\u00e4mpfung der Tuberkulose e.\u200aV. (DZK), Berlin"},{"name":"Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"ref1","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis \u2013 2011 update","author":"World Health Organization","year":"2011"},{"key":"ref2","volume-title":"Guidelines for treatment of tuberculosis","author":"World Health Organization","year":"2010","edition":"4. Aufl."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1055\/s-0042-118788","article-title":"Tuberkulosescreening bei Schwangeren im Kontext von \u00a736 (4) Infektionsschutzgesetz (IfSG)","volume":"70","author":"Deutsches Zentralkomitee zur Bek\u00e4mpfung der Tuberkulose (DZK)","year":"2016","journal-title":"Pneumologie"},{"key":"ref4","volume-title":"MIQ 05: Tuberkulose Mykobakteriose","author":"E Richter","year":"2019","edition":"3. Aufl."},{"key":"ref6","volume-title":"Tuberculosis in Switzerland: guidance for healthcare professionals","author":"O Schoch","year":"2019"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(12)70232-3","article-title":"Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis","volume":"13","author":"J L Davis","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis","volume":"63","author":"P Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00365548.2011.643820","article-title":"Diagnostic yield of post-bronchoscopy sputum smear in pulmonary tuberculosis","volume":"44","author":"M Malekmohammad","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4103\/0377-4929.168849","article-title":"Fluorescent microscopy and Ziehl-Neelsen staining of bronchoalveolar lavage, bronchial washings, bronchoscopic brushing and post bronchoscopic sputum along with cytological examination in cases of suspected tuberculosis","volume":"58","author":"V K Bodal","year":"2015","journal-title":"Indian J Pathol Microbiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-0031-1291582","article-title":"Infektionspr\u00e4vention bei Tuberkulose \u2013 Empfehlungen des DZK","volume":"66","author":"R Ziegler","year":"2012","journal-title":"Pneumologie"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0030-1256439","article-title":"Neue Empfehlungen f\u00fcr die Umgebungsuntersuchungen bei Tuberkulose","volume":"65","author":"R Diel","year":"2011","journal-title":"Pneumologie"},{"key":"ref16","first-page":"536","volume-title":"Mycobacterium: general characteristics, laboratory detection and staining procedures","author":"G Pfyffer","year":"2015"},{"issue":"S 01","key":"ref18","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1016\/j.ijmyco.2016.09.053","article-title":"Use of WGS in Mycobacterium tuberculosis routine diagnosis","volume":"5","author":"D M Cirillo","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1574-695X.2009.00555.x","article-title":"Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis","volume":"56","author":"J C Palomino","year":"2009","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref20","volume-title":"WHO consolidated guidelines on tuberculosis. Module 3: diagnosis \u2013 rapid diagnostics for tuberculosis detection","author":"World Health Organization","year":"2020"},{"key":"ref21","first-page":"Cd009593","article-title":"Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis","volume":"2","author":"J S Zifodya","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","first-page":"Cd012768","article-title":"Xpert MTB\/RIF Ultra and Xpert MTB\/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults","volume":"1","author":"M Kohli","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00292-021-00911-2","article-title":"Molekularpathologie der Tuberkulose: Stellenwert, Methodik und Grenzen","volume":"42","author":"F Stellmacher","year":"2021","journal-title":"Pathologe"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00292-021-00910-3","article-title":"Histopathologie der Lungentuberkulose","volume":"42","author":"F Stellmacher","year":"2021","journal-title":"Pathologe"},{"key":"ref25","volume-title":"Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB\/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update","author":"World Health Organization","year":"2013"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e0217597","DOI":"10.1371\/journal.pone.0217597","article-title":"First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017","volume":"14","author":"S Glasauer","year":"2019","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2000747","DOI":"10.1183\/13993003.00747-2020","article-title":"Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis","volume":"57","author":"M Kohli","year":"2021","journal-title":"Eur Respir J"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"707244","DOI":"10.3389\/fcimb.2021.707244","article-title":"A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB((R)) Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples","volume":"11","author":"I Bonnet","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2002338","DOI":"10.1183\/13993003.02338-2020","article-title":"Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs","volume":"57","author":"A Jouet","year":"2021","journal-title":"Eur Respir J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/JCM.02724-12","article-title":"Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs","volume":"51","author":"D J Horne","year":"2013","journal-title":"J Clin Microbiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JCM.00553-13","article-title":"Rifampin drug resistance tests for tuberculosis: challenging the gold standard","volume":"51","author":"A Van Deun","year":"2013","journal-title":"J Clin Microbiol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e01599-17","DOI":"10.1128\/JCM.01599-17","article-title":"Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis","volume":"56","author":"P Miotto","year":"2018","journal-title":"J Clin Microbiol"},{"key":"ref36","volume-title":"Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine)","author":"World Health Organization","year":"2021"},{"key":"ref37","volume-title":"Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis","author":"World Health Organisation","year":"2018"},{"key":"ref38","volume-title":"WHO operational handbook on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2020"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1128\/AAC.06460-11","article-title":"Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis","volume":"56","author":"L Fenner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.5588\/ijtld.16.0148","article-title":"Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation","volume":"20","author":"R Otto-Knapp","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e01798-18","DOI":"10.1128\/AAC.01798-18","article-title":"A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Low-Incidence Setting","volume":"63","author":"S Andres","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00204-15","article-title":"Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates","volume":"59","author":"S M Ramirez-Busby","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/JCM.02775-15","article-title":"Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis","volume":"54","author":"M R Farhat","year":"2016","journal-title":"J Clin Microbiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e0120470","DOI":"10.1371\/journal.pone.0120470","article-title":"Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review","volume":"10","author":"E Avalos","year":"2015","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"S Kadura","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1164\/rccm.201909-1819LE","article-title":"Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon","volume":"201","author":"S Andres","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/cid\/ciz074","article-title":"Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment","volume":"69","author":"S Polsfuss","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"MGM2-0014-2013","DOI":"10.1128\/microbiolspec.MGM2-0014-2013","article-title":"Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities","volume":"2","author":"C Vilcheze","year":"2014","journal-title":"Microbiol Spectr"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1901154","DOI":"10.1183\/13993003.01154-2019","article-title":"Accuracy of whole-genome sequencing to determine recent tuberculosis transmission: an 11-year population-based study in Hamburg, Germany","volume":"54","author":"R Diel","year":"2019","journal-title":"Eur Respir J"},{"key":"ref50","first-page":"2002272","article-title":"Use of a whole genome sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017\u20132019: an ECDC pilot study","volume":"57","author":"E Tagliani","year":"2021","journal-title":"Eur Respir J"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.cmi.2019.03.022","article-title":"Role and value of whole genome sequencing in studying tuberculosis transmission","volume":"25","author":"V Nikolayevskyy","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"ref52","first-page":"47","article-title":"The implications of whole-genome sequencing in the control of tuberculosis","volume":"3","author":"R S Lee","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"ref55","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update","author":"World Health Organization","year":"2017"},{"key":"ref56","first-page":"e93","article-title":"Treatment of Drug-Resistant Tuberculosis. An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline","volume":"200","author":"P Nahid","year":"2019","journal-title":"AJRCCM"},{"key":"ref57","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2020"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMra1413919","article-title":"Treatment of Tuberculosis","volume":"373","author":"C R Horsburgh Jr","year":"2015","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial","volume":"198","author":"G E Vel\u00e1squez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref60","volume-title":"Treatment of drug-susceptible TB: rapid communication","author":"World Health Organisation","year":"2021"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009913","article-title":"Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis","author":"C R Gallardo","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1183\/09031936.00033010","article-title":"Treatment of tuberculosis: update 2010","volume":"37","author":"W W Yew","year":"2011","journal-title":"Eur Respir J"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"H M Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref64","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/thx.2010.144295","article-title":"Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease","volume":"65","author":"H Milburn","year":"2010","journal-title":"Thorax"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"417","DOI":"10.20452\/pamw.985","article-title":"How should we treat tuberculosis in adult patients with chronic kidney disease? Key messages from the British Thoracic Society Guidelines","volume":"120","author":"H J Milburn","year":"2010","journal-title":"Pol Arch Med Wewn"},{"key":"ref67","volume-title":"Management of suspected drug-induced rash, kidney injury and liver injury in adult patients on TB treatment and\/or antiretroviral treatment","author":"National HIV & TB HCW Hotline MIC, Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town","year":"2018"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"W W Yew","year":"2006","journal-title":"Respirology"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1055\/a-1294-1580","article-title":"Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals","author":"R Diel","year":"2021","journal-title":"Pneumologie"},{"issue":"S 02","key":"ref70","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"K L Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"I Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-0029-1214673","article-title":"Empfehlungen f\u00fcr das Tuberkulosescreening vor Gabe von TNF-\u03b1-Inhibitoren bei rheumatischen Erkrankungen","volume":"63","author":"R Diel","year":"2009","journal-title":"Pneumologie"},{"key":"ref73","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2011","author":"J A Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"e012567","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-alpha antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Z Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","author":"L J Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3899\/jrheum.201251","article-title":"Tuberculosis in Biologic-na\u00efve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics","volume":"48","author":"J K Sundbaum","year":"2021","journal-title":"J Rheumatol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3899\/jrheum.140106","article-title":"Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment","volume":"91","author":"F Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3346\/jkms.2014.29.1.38","article-title":"Safe re-administration of tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFalpha therapy","volume":"29","author":"Y S Suh","year":"2014","journal-title":"J Korean Med Sci"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/rheumatology\/keu041","article-title":"Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors","volume":"53","author":"Y J Kim","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/tid.12436","article-title":"Latent tuberculosis in kidney and liver transplant patients: a review of treatment practices and outcomes","volume":"17","author":"S A Grim","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1183\/09031936.00000712","article-title":"The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement","volume":"40","author":"D Bumbacea","year":"2012","journal-title":"Eur Respir J"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008597","article-title":"Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis","author":"B Adamu","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/ajrccm\/143.2.262","article-title":"A controlled clinical comparison of 6 and 8 month of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong","volume":"143","author":"Hong Kong Chest Service","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"ofab565","DOI":"10.1093\/ofid\/ofab565","article-title":"Subsequent Antituberculous Treatment May Not Be Mandatory Among Surgically Resected Culture-Negative Pulmonary Granulomas: A Retrospective Nationwide Multicenter Cohort Study","volume":"8","author":"C L Chung","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5761\/atcs.oa.19-00199","article-title":"The Necessity of Anti-Tuberculosis Therapy after Resection of Pulmonary Tuberculous Nodules: A Single Center Retrospective Study","volume":"26","author":"C Wang","year":"2020","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"ref86","first-page":"51","article-title":"Long-term follow-up after thoracoscopic resection of solitary pulmonary tuberculoma","volume":"61","author":"T Laisaar","year":"2014","journal-title":"Indian J Tuberc"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1631\/jzus.B0820368","article-title":"Value of video-assisted thoracoscopic surgery in the diagnosis and treatment of pulmonary tuberculoma: 53 cases analysis and review of literature","volume":"10","author":"K Y Hsu","year":"2009","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200124070-00006","article-title":"Drug treatment for tuberculosis during pregnancy: safety considerations","volume":"24","author":"G Bothamley","year":"2001","journal-title":"Drug Saf"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0043-116545","article-title":"S2k-Leitlinie zur Diagnostik, Pr\u00e4vention und Therapie der Tuberkulose im Kindes- und Jugendalter","volume":"71","author":"C Feiterna-Sperling","year":"2017","journal-title":"Pneumologie"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"880","DOI":"10.5588\/ijtld.20.0122","article-title":"Breastfeeding in women living with tuberculosis","volume":"24","author":"M Loveday","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref91","first-page":"205","volume-title":"Adverse anti-tuberculosis drug events and their management","author":"J A Caminero","year":"2018"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"J J Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4102\/sajhivmed.v14i3.63","article-title":"Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB","volume":"14","author":"E Jong","year":"2013","journal-title":"Southern African Journal of HIV Medicine"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12879-015-0944-6","article-title":"A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection","volume":"15","author":"A J Hickey","year":"2015","journal-title":"BMC Infect Dis"},{"key":"ref95","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"R J Lehloenya","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2169\/internalmedicine.49.3590","article-title":"Desensitization therapy for allergic reactions to antituberculous drugs","volume":"49","author":"Y Kobashi","year":"2010","journal-title":"Intern Med"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/cea.14084","article-title":"Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs","volume":"52","author":"W H Bermingham","year":"2022","journal-title":"Clin Exp Allergy"},{"issue":"S 03","key":"ref99","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"J Grosset","year":"1983","journal-title":"Rev Infect Dis"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0007-0971(86)90066-5","article-title":"Ocular toxicity following ethambutol in standard dosage","volume":"80","author":"V K Chatterjee","year":"1986","journal-title":"Br J Dis Chest"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2169\/internalmedicine.6178-20","article-title":"Drastically Progressive Ethambutol-induced Optic Neuropathy after Withdrawal of Ethambutol: A Case Report and Literature Review","volume":"60","author":"T Matsumoto","year":"2021","journal-title":"Intern Med"},{"key":"ref102","first-page":"15","article-title":"Ocular ethambutol toxicity: is it reversible?","volume":"13","author":"A Kumar","year":"1993","journal-title":"J Clin Neuroophthalmol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/bjo.2008.148502","article-title":"Prospective evaluation of visual function for early detection of ethambutol toxicity","volume":"93","author":"V Menon","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0140-6736(55)92696-9","article-title":"Optic neuritis following isoniazid therapy","volume":"269","author":"J A Keeping","year":"1955","journal-title":"Lancet"},{"key":"ref105","first-page":"1013","article-title":"Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment","volume":"11","author":"G Karmon","year":"1979","journal-title":"Ann Ophthalmol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0041-3879(80)90038-0","article-title":"Pyridoxine supplementation during isoniazid therapy","volume":"61","author":"D E Snider Jr","year":"1980","journal-title":"Tubercle"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bcp.12720","article-title":"Treatment of drug-induced seizures","volume":"81","author":"H Y Chen","year":"2016","journal-title":"British journal of clinical pharmacology"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.genhosppsych.2013.03.018","article-title":"A review of the interplay between tuberculosis and mental health","volume":"35","author":"A M Doherty","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"ref109","first-page":"679","article-title":"Drug-induced hyperuricaemia and gout","volume":"56","author":"C Ben Salem","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-199835020-00001","article-title":"Chronopharmacokinetics","volume":"35","author":"B Bruguerolle","year":"1998","journal-title":"Current status. Clin Pharmacokinet"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12879-018-3654-z","article-title":"Pleural IFN-\u03b3 release assay combined with biomarkers distinguished effectively tuberculosis from malignant pleural effusion","volume":"19","author":"Y Tang","year":"2019","journal-title":"BMC Infect Dis"},{"key":"ref112","first-page":"CD001876","article-title":"Corticosteroids for tuberculous pleurisy","volume":"3","author":"H Ryan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.rmed.2008.01.018","article-title":"The use of adjunctive corticosteroids in the treatment of pericardial, pleural and meningeal tuberculosis: do they improve outcome?","volume":"102","author":"D J Evans","year":"2008","journal-title":"Respir Med"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1024\/1661-8157\/a000242","article-title":"Therapie einer Lymphknotentuberkulose","volume":"99","author":"R S Sellar","year":"2010","journal-title":"Praxis (Bern 1994)"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"71","author":"C L Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"677","DOI":"10.5588\/ijtld.16.0927","article-title":"Paradoxical upgrading reaction in extra-pulmonary tuberculosis: association with vitamin D therapy","volume":"21","author":"D A Barr","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s15010-017-1112-2","article-title":"Vacuum-assisted closure therapy of paradoxical reaction in tuberculous lymphadenopathy caused by Mycobacterium africanum","volume":"46","author":"H F Geerdes-Fenge","year":"2018","journal-title":"Infection"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.eururo.2005.03.008","article-title":"EAU guidelines for the management of genitourinary tuberculosis","volume":"48","author":"M Cek","year":"2005","journal-title":"Eur Urol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ajg.2008.162","article-title":"Differentiating intestinal tuberculosis from Crohn\u02bcs disease: a diagnostic challenge","volume":"104","author":"M A Almadi","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref120","first-page":"CD012163","article-title":"Six-month therapy for abdominal tuberculosis","volume":"11","author":"S Jullien","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref121","first-page":"CD000526","article-title":"Interventions for treating tuberculous pericarditis","volume":"9","author":"C S Wiysonge","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pcad.2007.03.002","article-title":"A modern approach to tuberculous pericarditis","volume":"50","author":"F F Syed","year":"2007","journal-title":"Prog Cardiovasc Dis"},{"key":"ref123","volume-title":"Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE clinical guideline 117","author":"National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE","year":"2011"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jac\/29.6.719","article-title":"Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges","volume":"29","author":"R Nau","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"e42745","DOI":"10.1371\/journal.pone.0042745","article-title":"Cerebrospinal fluid glucose and lactate: age-specific reference values and implications for clinical practice","volume":"7","author":"W G Leen","year":"2012","journal-title":"PLoS One"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"R Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tube.2010.07.003","article-title":"The chemotherapy of tuberculous meningitis in children and adults","volume":"90","author":"P R Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"P R Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis","volume":"374","author":"A D Heemskerk","year":"2016","journal-title":"N Engl J Med"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jinf.2009.06.011","article-title":"British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children","volume":"59","author":"G Thwaites","year":"2009","journal-title":"J Infect"},{"key":"ref131","first-page":"CD002244","article-title":"Corticosteroids for managing tuberculous meningitis","volume":"4","author":"K Prasad","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"292","DOI":"10.12688\/wellcomeopenres.16474.1","article-title":"Host Directed Therapies for Tuberculous Meningitis","volume":"5","author":"A G Davis","year":"2020","journal-title":"Wellcome Open Res"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"ofaa604","DOI":"10.1093\/ofid\/ofaa604","article-title":"Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions","volume":"8","author":"B J Marais","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"M Babjuk","year":"2013","journal-title":"Eur Urol"},{"issue":"S 01","key":"ref135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000052381","article-title":"BCG intravesical instillations: recommendations for side-effects management","volume":"37","author":"P Rischmann","year":"2000","journal-title":"Eur Urol"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy \u2013 Associated Adverse Events","volume":"7","author":"F Witjes","year":"2008","journal-title":"European Urology supplements"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0022-5347(05)68078-0","article-title":"Interference of modern antibacterials with bacillus Calmette-Guerin viability","volume":"162","author":"C Durek","year":"1999","journal-title":"J Urol"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0094-0143(21)00423-7","article-title":"Complications of bacillus Calmette-Guerin immunotherapy","volume":"19","author":"D L Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"D L Lamm","year":"1992","journal-title":"J Urol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1128\/AAC.40.7.1610","article-title":"In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis","volume":"40","author":"N Rastogi","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0022-5347(05)64751-9","article-title":"Optimal treatment of systemic bacillus Calmette-Guerin infection: investigations in an animal model","volume":"168","author":"C Durek","year":"2002","journal-title":"J Urol"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"A Bohle","year":"2003","journal-title":"J Urol"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1055\/s-0043-115775","article-title":"BCGitis mit Lungen-, Leber- und Knochenmarksbeteiligung nach Immuntherapie eines Urothelkarzinoms","volume":"142","author":"H F Geerdes-Fenge","year":"2017","journal-title":"Dtsch Med Wochenschr"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/2152-7806.89879","article-title":"Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guerin therapy","volume":"2","author":"S Obaid","year":"2011","journal-title":"Surg Neurol Int"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"2100361","DOI":"10.1183\/13993003.00361-2021","article-title":"New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization","volume":"57","author":"K Viney","year":"2021","journal-title":"Eur Respir J"},{"key":"ref147","volume-title":"Bericht zur Epidemiologie der Tuberkulose in Deutschland f\u00fcr 2019","author":"Robert Koch-Institut","year":"2020"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3201\/eid2103.141343","article-title":"Multidrug-resistant tuberculosis in Europe, 2010\u20132011","volume":"21","author":"G G\u00fcnther","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis","volume":"6","author":"F Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"N Ahmad","year":"2018","journal-title":"Lancet"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab359","article-title":"Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing","author":"H P Grobbel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03492-2020","article-title":"Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model","author":"J Heyckendorf","year":"2021","journal-title":"Eur Respir J"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","author":"F Mirzayev","year":"2020","journal-title":"Eur Respir J"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0034-1377226","article-title":"Resistenzen gegen Zweitlinienmedikamente bei Migranten mit multiresistenter Tuberkulose in der Region Berlin","volume":"68","author":"R Otto-Knapp","year":"2014","journal-title":"Pneumologie"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1164\/rccm.201606-1097LE","article-title":"Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe","volume":"194","author":"C Lange","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","volume":"382","author":"F Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"ref158","volume-title":"Rapid communication: key changes to the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2022"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02544-2020","article-title":"Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country","author":"D Chesov","year":"2020","journal-title":"Eur Respir J"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"1700742","DOI":"10.1183\/13993003.00742-2017","article-title":"Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis","volume":"49","author":"I D Olaru","year":"2017","journal-title":"Eur Respir J"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12884-021-03956-6","article-title":"Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa","volume":"21","author":"I Mokhele","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/cid\/civ991","article-title":"Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel","volume":"62","author":"A Gupta","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/cid\/ciaa189","article-title":"Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug\/Rifampicin-Resistant Tuberculosis in South Africa","volume":"72","author":"M Loveday","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/QAD.0000000000001016","article-title":"Impact of HIV infection on treatment outcome of tuberculosis in Europe","volume":"30","author":"B Karo","year":"2016","journal-title":"Aids"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14740338.2020.1694901","article-title":"Safety implications of combined antiretroviral and anti-tuberculosis drugs","volume":"19","author":"M Cerrone","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"K Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"ref168","first-page":"52","article-title":"High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen","author":"N Ndjeka","year":"2018","journal-title":"Eur Respir J"},{"key":"ref170","first-page":"54","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","author":"S Borisov","year":"2019","journal-title":"Eur Respir J"},{"key":"ref171","volume-title":"Active tuberculosis drug-safety monitoring and management (aDSM) \u2013 Framework for implementation","author":"World Health Organisation","year":"2015"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/microbiolspec.TNMI7-0028-2016","article-title":"Tuberculosis Associated with HIV Infection","author":"J A Tornheim","year":"2017","journal-title":"Microbiol Spectr"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.qai.0000230521.86964.86","article-title":"Survival rate and risk factors of mortality among HIV\/tuberculosis-coinfected patients with and without antiretroviral therapy","volume":"43","author":"W Manosuthi","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2334-9-46","article-title":"Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database","volume":"9","author":"J Zhou","year":"2009","journal-title":"BMC Infect Dis"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"e49111","DOI":"10.1371\/journal.pone.0049111","article-title":"HIV-prevalence in tuberculosis patients in Germany, 2002-2009: an estimation based on HIV and tuberculosis surveillance data","volume":"7","author":"L Fiebig","year":"2012","journal-title":"PLoS One"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1164\/ajrccm\/146.1.53","article-title":"Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation","volume":"146","author":"J Batungwanayo","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/ajrccm\/148.5.1292","article-title":"Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection","volume":"148","author":"B E Jones","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00408-012-9440-6","article-title":"Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis","volume":"191","author":"C Naing","year":"2013","journal-title":"Lung"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/cid\/cis303","article-title":"Site of extrapulmonary tuberculosis is associated with HIV infection","volume":"55","author":"I L Leeds","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/S0882-0546(03)00072-0","article-title":"Clinical and radiographic features of HIV-related tuberculosis","volume":"18","author":"W J Burman","year":"2003","journal-title":"Semin Respir Infect"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"A M Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"M Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40262-018-0716-8","article-title":"A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs","volume":"58","author":"A Daskapan","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cis630","article-title":"An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection","volume":"55","author":"F Ahmad Khan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(19)30154-7","article-title":"Management of active tuberculosis in adults with HIV","volume":"6","author":"G Meintjes","year":"2019","journal-title":"Lancet HIV"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/cid\/ciu674","article-title":"Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy","volume":"59","author":"G Narendran","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/M14-2979","article-title":"Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis","volume":"163","author":"O A Uthman","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/2325957415599210","article-title":"The Effect of Early Initiation of Antiretroviral Therapy in TB\/HIV-Coinfected Patients: A Systematic Review and Meta-Analysis","volume":"14","author":"S M Abay","year":"2015","journal-title":"Journal of the International Association of Providers of AIDS Care"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"D V Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"S S Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"F X Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/fmb.15.9","article-title":"Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis","volume":"10","author":"P E Namale","year":"2015","journal-title":"Future Microbiol"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.amsu.2020.05.004","article-title":"Effects of time of initiation of antiretroviral therapy in the treatment of patients with HIV\/TB co-infection: A systemic review and meta-analysis","volume":"55","author":"L Chelkeba","year":"2020","journal-title":"Ann Med Surg (Lond)"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1473-3099(14)70733-9","article-title":"Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial","volume":"14","author":"S G Mfinanga","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12879-018-3256-9","article-title":"HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town","volume":"18","author":"R Kaplan","year":"2018","journal-title":"BMC Infect Dis"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis","volume":"52","author":"M E Torok","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"S S Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"A Boulle","year":"2008","journal-title":"Jama"},{"key":"ref206","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","article-title":"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial","volume":"14","author":"B Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"ref207","first-page":"549","article-title":"Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial","volume":"70","author":"K E Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref208","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/QAI.0000000000002126","article-title":"Clinical and Virological Outcomes of TB\/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana","volume":"82","author":"C Modongo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref209","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1473-3099(20)30869-0","article-title":"Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12\u2008300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial","volume":"21","author":"N De Castro","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/jac\/dkz217","article-title":"Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting","volume":"74","author":"C Barcelo","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","article-title":"Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings","volume":"8","author":"G Meintjes","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"ref212","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","article-title":"Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome","volume":"24","author":"G Meintjes","year":"2010","journal-title":"AIDS (London, England)"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1164\/rccm.201201-0094OC","article-title":"Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome","volume":"186","author":"G Meintjes","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"ref214","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1800762","article-title":"Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS","volume":"379","author":"G Meintjes","year":"2018","journal-title":"N Engl J Med"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/cid\/ciz942","article-title":"Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis","volume":"70","author":"J C Alffenaar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref217","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"S Srivastava","year":"2011","journal-title":"J Infect Dis"},{"key":"ref218","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy","volume":"55","author":"J G Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref219","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes","volume":"208","author":"J G Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"ref220","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1569","article-title":"Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response","author":"X Zheng","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/jcph.968","article-title":"A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis","volume":"57","author":"A Naidoo","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"ref222","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1128\/AAC.05792-11","article-title":"A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients","volume":"56","author":"W Smythe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref223","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"J Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"ref224","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1183\/13993003.01285-2015","article-title":"End TB with precision treatment!","volume":"47","author":"E P van der Burgt","year":"2016","journal-title":"Eur Respir J"},{"key":"ref225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijid.2014.12.001","article-title":"Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment","volume":"32","author":"G Sotgiu","year":"2015","journal-title":"Int J Infect Dis"},{"key":"ref226","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17425255.2021.1836158","article-title":"Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems","volume":"17","author":"A G M\u00e4rtson","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref227","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","article-title":"Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin","volume":"44","author":"C Magis-Escurra","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"ref228","doi-asserted-by":"crossref","first-page":"e00384-19","DOI":"10.1128\/AAC.00384-19","article-title":"Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients","volume":"63","author":"S HJ van den Elsen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref229","doi-asserted-by":"crossref","first-page":"e01092-18","DOI":"10.1128\/AAC.01092-18","article-title":"Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients","volume":"62","author":"S HJ van den Elsen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref230","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","article-title":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","volume":"49","author":"J Kamp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2015.06.008","article-title":"Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis","volume":"46","author":"J A Dijkstra","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"ref232","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1183\/09031936.00177014","article-title":"An interlaboratory quality control programme for the measurement of tuberculosis drugs","volume":"46","author":"R E Aarnoutse","year":"2015","journal-title":"Eur Respir J"},{"key":"ref233","doi-asserted-by":"crossref","first-page":"948","DOI":"10.5588\/ijtld.19.0759","article-title":"Length of hospital stay for TB varies with comorbidity and hospital location","volume":"24","author":"S Tonko","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref234","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pulmoe.2020.12.016","article-title":"Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence","volume":"27","author":"G B Migliori","year":"2021","journal-title":"Pulmonology"},{"key":"ref235","first-page":"6","article-title":"Cost of illness of non-multidrug-resistant tuberculosis in Germany: an update","author":"R Diel","year":"2020","journal-title":"ERJ Open Res"},{"key":"ref236","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/09031936.00204611","article-title":"Tuberculosis: cost of illness in Germany","volume":"40","author":"R Diel","year":"2012","journal-title":"Eur Respir J"},{"key":"ref237","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2191-1991-2-15","article-title":"Assessing DRG cost accounting with respect to resource allocation and tariff calculation: the case of Germany","volume":"2","author":"M Vogl","year":"2012","journal-title":"Health Econ Rev"},{"key":"ref238","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.rmed.2014.09.021","article-title":"Cost of multi drug resistance tuberculosis in Germany","volume":"108","author":"R Diel","year":"2014","journal-title":"Respir Med"},{"key":"ref239","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.rmed.2015.01.017","article-title":"Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba\u2122 to background regimens in Germany","volume":"109","author":"R Diel","year":"2015","journal-title":"Respir Med"},{"key":"ref240","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-47186-9","volume-title":"Arzneiverordnungs-Report 2015","author":"U Schwabe","year":"2015","edition":"1. Aufl."},{"key":"ref241","first-page":"102","article-title":"Cost of multidrug resistant tuberculosis in Germany \u2013 An update","volume":"103","author":"R Diel","year":"2021","journal-title":"IJID"},{"key":"ref243","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.4103\/0366-6999.170255","article-title":"Adjuvant Efficacy of Nutrition Support During Pulmonary Tuberculosis Treating Course: Systematic Review and Meta-analysis","volume":"128","author":"Z-L Si","year":"2015","journal-title":"Chin Med J"},{"key":"ref244","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJMoa1915176","article-title":"Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease","volume":"383","author":"D Ganmaa","year":"2020","journal-title":"N Engl J Med"},{"key":"ref245","doi-asserted-by":"crossref","first-page":"e1002907","DOI":"10.1371\/journal.pmed.1002907","article-title":"Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis","volume":"16","author":"O Aibana","year":"2019","journal-title":"PLoS Med"},{"key":"ref246","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(14)70033-5","article-title":"Progress in tuberculosis vaccine development and host-directed therapies \u2013 a state of the art review","volume":"2","author":"S HE Kaufmann","year":"2014","journal-title":"Lancet Respir Med"},{"key":"ref247","volume-title":"Vitamin D und Pra\u0308vention ausgewa\u0308hlter chronischer Krankheiten","author":"J Linseisen","year":"2011"},{"key":"ref248","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/13548506.2012.726364","article-title":"Prevalence of post-traumatic stress symptoms and associated factors in tuberculosis (TB), TB retreatment and\/or TB\u2013HIV co-infected primary public health-care patients in three districts in South Africa","volume":"18","author":"K Peltzer","year":"2013","journal-title":"Psychol Health Med"},{"key":"ref249","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0041-109601","article-title":"Tuberkulose und Rauchen","volume":"70","author":"R Loddenkemper","year":"2016","journal-title":"Pneumologie"},{"key":"ref250","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5588\/ijtld.19.0002","article-title":"The impact of smoking on tuberculosis treatment outcomes: a meta-analysis","volume":"24","author":"E Y Wang","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1183\/09031936.00072909","article-title":"Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD","volume":"35","author":"R N van Zyl Smit","year":"2010","journal-title":"Eur Respir J"},{"key":"ref253","first-page":"20","article-title":"Surgical treatment of pulmonary tuberculosis","volume":"61","author":"P Yablonski","year":"2013","journal-title":"Eur Respir Monogr"},{"key":"ref254","first-page":"182","article-title":"Thoracic surgery for haemoptysis in the context of tuberculosis: what is the best management approach?","volume":"6","author":"S Halezeroglu","year":"2014","journal-title":"J Thorac Dis"},{"key":"ref255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1749-8090-8-180","article-title":"Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence -- a National Centre\u02bcs experience","volume":"8","author":"S Farid","year":"2013","journal-title":"J Cardiothorac Surg"},{"key":"ref256","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.athoracsur.2010.02.037","article-title":"Surgery for pulmonary aspergilloma in immunocompetent patients: no benefit from adjuvant antifungal pharmacotherapy","volume":"89","author":"D Sagan","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"ref257","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1159\/000512531","article-title":"Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge","volume":"100","author":"B W Allwood","year":"2021","journal-title":"Respiration"},{"key":"ref258","doi-asserted-by":"crossref","first-page":"820","DOI":"10.5588\/ijtld.20.0067","article-title":"Post-tuberculosis lung health: perspectives from the First International Symposium","volume":"24","author":"B W Allwood","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref259","doi-asserted-by":"crossref","first-page":"1900495","DOI":"10.1183\/13993003.00495-2019","article-title":"Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study","volume":"56","author":"S Datta","year":"2020","journal-title":"Eur Respir J"},{"key":"ref260","doi-asserted-by":"crossref","first-page":"712","DOI":"10.5588\/ijtld.12.0267","article-title":"Declaration on palliative care and MDR\/XDR-TB","volume":"16","author":"S Connor","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"700","DOI":"10.5588\/ijtld.19.0809","article-title":"Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis","volume":"24","author":"M Mu\u00f1oz-Torrico","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref262","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5588\/ijtld.20.0906","article-title":"Persistent chronic respiratory symptoms despite TB cure is poorly correlated with lung function","volume":"25","author":"B W Allwood","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref263","doi-asserted-by":"crossref","first-page":"797","DOI":"10.5588\/ijtld.21.0425","article-title":"Clinical standards for the assessment, management and rehabilitation of post-TB lung disease","volume":"25","author":"G B Migliori","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref264","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1183\/09031936.00116808","article-title":"Quality of life measured by the St George\u02bcs Respiratory Questionnaire and spirometry","volume":"33","author":"M Weatherall","year":"2009","journal-title":"Eur Respir J"},{"key":"ref266","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jval.2011.11.035","article-title":"The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF","volume":"15","author":"N S da Rocha","year":"2012","journal-title":"Value Health"},{"key":"ref267","doi-asserted-by":"crossref","first-page":"881","DOI":"10.5588\/ijtld.18.0428","article-title":"Palliative care and symptom relief for people affected by multidrug-resistant tuberculosis","volume":"23","author":"E L Krakauer","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref269","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5414\/ATX02512","article-title":"Palliative Care in der pneumologischen Infektiologie","volume":"46","author":"N Sch\u00f6nfeld","year":"2020","journal-title":"Atemwegs- und Lungenkrankheiten"},{"key":"ref270","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5588\/ijtld.18.0622","article-title":"Management of patients with multidrug-resistant tuberculosis","volume":"23","author":"C Lange","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref271","volume-title":"Roadmap to Prevent and Combat Drug-resistant Tuberculosis","author":"World Health Organization Regional Office for Europe","year":"2011"},{"key":"ref272","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1473-3099(12)70084-1","article-title":"Palliative and end-of-life care in the global response to multidrug-resistant tuberculosis","volume":"12","author":"R Harding","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref273","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5588\/ijtld.21.0753","article-title":"Clinical standards for the diagnosis, treatment and prevention of TB infection","volume":"26","author":"G B Migliori","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref274","first-page":"1","article-title":"Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli","volume":"19","author":"I Sutherland","year":"1976","journal-title":"Adv Tuberc Res"},{"key":"ref275","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/ajrccm.153.1.8542139","article-title":"Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis","volume":"153","author":"A L Kritski","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"ref276","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup","volume":"179","author":"K M Shea","year":"2014","journal-title":"Am J Epidemiol"},{"key":"ref277","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJM200107193450307","article-title":"Management of tuberculosis in the United States","volume":"345","author":"P M Small","year":"2001","journal-title":"N Engl J Med"},{"key":"ref278","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1164\/rccm.200711-1613OC","article-title":"Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis","volume":"177","author":"R Diel","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"ref279","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00205512","article-title":"Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination","volume":"42","author":"R Diel","year":"2013","journal-title":"Eur Respir J"},{"key":"ref280","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1183\/13993003.01012-2016","article-title":"Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis","volume":"48","author":"E Petruccioli","year":"2016","journal-title":"Eur Respir J"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"M Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref283","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","article-title":"Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam","volume":"190","author":"R Sloot","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"ref284","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1473-3099(21)00261-9","article-title":"The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-\u03b3 release assays: a systematic review and meta-analysis","volume":"22","author":"M Krutikov","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref285","volume-title":"Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection","author":"World Health Organization","year":"2022"},{"key":"ref286","doi-asserted-by":"crossref","first-page":"m549","DOI":"10.1136\/bmj.m549","article-title":"Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis","volume":"368","author":"J R Campbell","year":"2020","journal-title":"BMJ"},{"key":"ref287","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1183\/13993003.01047-2015","article-title":"Numbers needed to treat to prevent tuberculosis","volume":"46","author":"M Sester","year":"2015","journal-title":"Eur Respir J"},{"key":"ref288","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2214-109X(18)30487-X","article-title":"Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2\u00b73 million patients with tuberculosis","volume":"7","author":"J J Noubiap","year":"2019","journal-title":"Lancet Glob Health"},{"key":"ref289","first-page":"1039","article-title":"Isoniazid preventive therapy: Retrospect and prospect","volume":"121","author":"L A Dash","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"ref290","first-page":"27","article-title":"Tuberculosis in pregnant women and neonates: A meta-review of current evidence","volume":"36","author":"K Snow","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"ref291","volume-title":"WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment","author":"World Health Organization","year":"2020"},{"key":"ref292","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000171","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","author":"M J Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"ref293","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000171.pub3","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","author":"C Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref294","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"T R Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"ref295","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41591-020-1076-0","article-title":"Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings","volume":"26","author":"R K Gupta","year":"2020","journal-title":"Nat Med"},{"key":"ref296","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrmicro.2017.128","article-title":"Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection","volume":"16","author":"L CK Bell","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"ref297","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/QAD.0000000000002599","article-title":"Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom","volume":"34","author":"C L van Halsema","year":"2020","journal-title":"Aids"},{"key":"ref298","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/14787210.2016.1168693","article-title":"Screening and treatment of latent tuberculosis infection among HIV-infected patients in resource-rich settings","volume":"14","author":"A W Lin","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref299","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1086\/510080","article-title":"Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission","volume":"44","author":"L Elzi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref300","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/cid\/ciu849","article-title":"Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB\/HIV in Rio (THRio) study","volume":"60","author":"J E Golub","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2334-14-148","article-title":"Tuberculosis among people living with HIV\/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors","volume":"14","author":"B Karo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"ref302","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12879-017-2627-y","article-title":"Immunological recovery in tuberculosis\/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy","volume":"17","author":"B Karo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"ref303","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","article-title":"Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis","volume":"12","author":"M X Rangaka","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref304","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jinf.2020.02.009","article-title":"Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection","volume":"80","author":"E Petruccioli","year":"2020","journal-title":"J Infect"},{"key":"ref305","doi-asserted-by":"crossref","first-page":"e0188631","DOI":"10.1371\/journal.pone.0188631","article-title":"Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis","volume":"12","author":"T N Doan","year":"2017","journal-title":"PLoS One"},{"key":"ref306","first-page":"165","article-title":"[Recommendations for use of rituximab in patients with rheumatoid arthritis]","volume":"73","author":"A Rubbert-Roth","year":"2014","journal-title":"Z Rheumatol"},{"key":"ref307","first-page":"1245","article-title":"[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany]","volume":"90","author":"S Bittner","year":"2019","journal-title":"Nervenarzt"},{"issue":"S 02","key":"ref308","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"M Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"ref309","doi-asserted-by":"crossref","first-page":"8909834","DOI":"10.1155\/2017\/8909834","article-title":"Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics","volume":"2017","author":"F Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"key":"ref310","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thoraxjnl-2016-209397","article-title":"Corticosteroids and infliximab impair the performance of interferon-gamma release assays used for diagnosis of latent tuberculosis","volume":"72","author":"A Edwards","year":"2017","journal-title":"Thorax"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","article-title":"High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy","volume":"2","author":"W S Mow","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref312","first-page":"236","article-title":"[Infections]","volume":"78","author":"H M Lorenz","year":"2019","journal-title":"Z Rheumatol"},{"key":"ref313","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","article-title":"Risk assessment of tuberculosis in immunocompromised patients. A TBNET study","volume":"190","author":"M Sester","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"ref314","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00277-020-04191-3","article-title":"Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study","volume":"99","author":"F Bettelli","year":"2020","journal-title":"Ann Hematol"},{"key":"ref315","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cid\/ciz048","article-title":"Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation","volume":"69","author":"M P Cheng","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref316","doi-asserted-by":"crossref","first-page":"e2014026","DOI":"10.4084\/mjhid.2014.026","article-title":"Tuberculosis in patients with haematological malignancies","volume":"6","author":"L Anibarro","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref317","first-page":"1110","article-title":"Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances","volume":"90","author":"F A Silva","year":"2005","journal-title":"Haematologica"},{"key":"ref318","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12794","article-title":"Incidence and clinical profile of tuberculosis after allogeneic stem cell transplantation","volume":"20","author":"N Agrawal","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"ref319","doi-asserted-by":"crossref","first-page":"e0173250","DOI":"10.1371\/journal.pone.0173250","article-title":"The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population","volume":"12","author":"H J Lee","year":"2017","journal-title":"PLoS One"},{"key":"ref320","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5588\/ijtld.14.0301","article-title":"Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study","volume":"19","author":"W C Fan","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1086\/599035","article-title":"Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort","volume":"48","author":"J Torre-Cisneros","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref322","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1600-6143.2004.00545.x","article-title":"Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998\u20132000","volume":"4","author":"M M Klote","year":"2004","journal-title":"Am J Transplant"},{"key":"ref323","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/ije\/dyaa063","article-title":"Long-term risk of tuberculosis among migrants according to migrant status: a cohort study","volume":"49","author":"K L Kristensen","year":"2020","journal-title":"Int J Epidemiol"},{"key":"ref324","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1016\/S0140-6736(16)31008-X","article-title":"Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519\u2008955 migrants screened before entry to England, Wales, and Northern Ireland","volume":"388","author":"R W Aldridge","year":"2016","journal-title":"Lancet"},{"key":"ref325","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3201\/eid2604.190123","article-title":"High Incidence of Active Tuberculosis in Asylum Seekers from Eritrea and Somalia in the First 5 Years after Arrival in the Netherlands","volume":"26","author":"J van den Boogaard","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"ref326","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/a-0946-0239","article-title":"Kontaktuntersuchungen bei aktiver Tuberkulose und Management latenter Tuberkulose: 5 Jahres-Analyse an einem deutschen Gro\u00dfstadt Gesundheitsamt","volume":"82","author":"F Neuhann","year":"2020","journal-title":"Gesundheitswesen"},{"key":"ref327","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","author":"World Health Organization","year":"2018"},{"key":"ref328","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1086\/594126","article-title":"Tuberculosis and illicit drug use: review and update","volume":"48","author":"R G Deiss","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref329","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00103-019-02977-z","article-title":"Die Tuberkulosesituation im Berliner Justizvollzug 2011\u20132016 \u2013 Eine Folgeerhebung","volume":"62","author":"S Pape","year":"2019","journal-title":"Bundesgesundheitsblatt\u2013 Gesundheitsforschung \u2013 Gesundheitsschutz"},{"key":"ref330","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.5588\/ijtld.13.0270","article-title":"Tuberculosis among the homeless, United States, 1994\u20132010","volume":"17","author":"S Bamrah","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref331","first-page":"464","article-title":"Tuberculosis testing in correctional officers: a national random survey of jails in the United States","volume":"14","author":"I A Binswanger","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref332","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1183\/09031936.00120908","article-title":"LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement","volume":"33","author":"U Mack","year":"2009","journal-title":"Eur Respir J"},{"key":"ref333","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"G W Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref334","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"H Getahun","year":"2015","journal-title":"Eur Respir J"},{"key":"ref335","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: a network meta-analysis","volume":"161","author":"H R Stagg","year":"2014","journal-title":"Ann Intern Med"},{"key":"ref336","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis","volume":"380","author":"S Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"ref337","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults","volume":"379","author":"D Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"ref338","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"T R Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"ref339","doi-asserted-by":"crossref","first-page":"e91024","DOI":"10.1371\/journal.pone.0091024","article-title":"Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans","volume":"9","author":"R Colangeli","year":"2014","journal-title":"PLoS One"},{"key":"ref340","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.811","article-title":"Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection","volume":"43","author":"C B Ford","year":"2011","journal-title":"Nat Genet"},{"key":"ref341","volume-title":"Tuberkulose und nicht tuberkul\u00f6se mykobakterielle Krankheiten","author":"K Magdorf","year":"2009"},{"key":"ref342","volume-title":"Latent Tuberculosis Infection: A Guide For Primary Health Care Providers","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"ref343","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1183\/09031936.00079310","article-title":"Treatment of latent infection with Mycobacterium tuberculosis: update 2010","volume":"37","author":"C C Leung","year":"2011","journal-title":"Eur Respir J"},{"key":"ref344","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis","volume":"64","author":"S M Marks","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref345","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ijid.2020.01.042","article-title":"MDR\/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network","volume":"92S","author":"G B Migliori","year":"2020","journal-title":"Int J Infect Dis"},{"key":"ref346","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/1471-0528.14408","article-title":"Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis","volume":"124","author":"S Sobhy","year":"2017","journal-title":"BJOG"},{"key":"ref347","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"2020","author":"T RNG Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"ref348","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"ref349","volume-title":"Latent Tuberculosis Infection: A Guide for Primary Health Care Providers","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"ref350","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1086\/313891","article-title":"Treatment of latent tuberculosis infection: renewed opportunity for tuberculosis control","volume":"31","author":"D L Cohn","year":"2000","journal-title":"Clin Infect Dis"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/518974","article-title":"Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002\u20132005","volume":"45","author":"A Gupta","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref352","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/cid\/cis732","article-title":"Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps","volume":"55","author":"J S Mathad","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref354","doi-asserted-by":"crossref","first-page":"e0154825","DOI":"10.1371\/journal.pone.0154825","article-title":"Latent Tuberculosis in Pregnancy: A Systematic Review","volume":"11","author":"I Malhame","year":"2016","journal-title":"PLoS One"},{"key":"ref355","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000086261","article-title":"Review of epidemiological studies on the occupational risk of tuberculosis in low-incidence areas","volume":"72","author":"A Seidler","year":"2005","journal-title":"Respiration"},{"key":"ref356","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1378\/chest.11-3157","article-title":"Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis","volume":"142","author":"R Diel","year":"2012","journal-title":"Chest"},{"key":"ref358","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00420-007-0212-1","article-title":"Evaluation of the interferon-gamma release assay in healthcare workers","volume":"81","author":"A Nienhaus","year":"2008","journal-title":"Int Arch Occup Environ Health"},{"key":"ref359","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.3390\/ijerph17134643","article-title":"Risk Analysis of Latent Tuberculosis Infection among Health Workers Compared to Employees in Other Sectors","volume":"17","author":"L Hermes","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"ref360","doi-asserted-by":"crossref","first-page":"e115322","DOI":"10.1371\/journal.pone.0115322","article-title":"Occupational screening for tuberculosis and the use of a borderline zone for interpretation of the IGRA in German healthcare workers","volume":"9","author":"A Schablon","year":"2014","journal-title":"PloS one"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1745-6673-6-19","article-title":"Screening for tuberculosis and prediction of disease in Portuguese healthcare workers","volume":"6","author":"J Torres Costa","year":"2011","journal-title":"J Occup Med Toxicol"},{"key":"ref362","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"D E Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"ref363","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/647944","article-title":"4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity","volume":"49","author":"P D Ziakas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref364","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"D Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"ref365","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/thx.2009.125054","article-title":"Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB","volume":"65","author":"A Aspler","year":"2010","journal-title":"Thorax"},{"key":"ref366","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis","volume":"40","author":"J Ena","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref367","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0031-1291619","article-title":"Empfehlungen zur Therapie, Chemopr\u00e4vention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter","volume":"66","author":"T Schaberg","year":"2012","journal-title":"Pneumologie"},{"key":"ref368","first-page":"509","article-title":"Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland","volume":"35","author":"O Horwitz","year":"1966","journal-title":"Bull World Health Organ"},{"key":"ref369","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska","volume":"95","author":"G W Comstock","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"ref370","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies","volume":"119","author":"G W Comstock","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200111090-00009","article-title":"Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults","volume":"15","author":"J L Johnson","year":"2001","journal-title":"AIDS (London, England)"},{"key":"ref372","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cid\/ciu186","article-title":"The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study","volume":"58","author":"F M Marx","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref373","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"B J Drew","year":"2010","journal-title":"Circulation"},{"key":"ref374","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"K E Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ref375","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/cid\/ciab335","article-title":"Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study","volume":"73","author":"J CM Brust","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref376","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/a-0880-9987","article-title":"Gemeinsame Stellungnahme zur neuen Empfehlung der WHO zur Behandlung der multiresistenten und Rifampicin-resistenten Tuberkulose","volume":"73","author":"F P Maurer","year":"2019","journal-title":"Pneumologie"},{"key":"ref377","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"R P van Heeswijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref378","doi-asserted-by":"crossref","first-page":"1901908","DOI":"10.1183\/13993003.01908-2019","article-title":"Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?","volume":"55","author":"J C Alffenaar","year":"2020","journal-title":"Eur Respir J"},{"key":"ref379","volume-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis","author":"World Health Organization","year":"2014"},{"key":"ref380","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00009-2020","article-title":"Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany","author":"B H\u00e4cker","year":"2020","journal-title":"Eur Respir J"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1800017","DOI":"10.1183\/13993003.00017-2018","article-title":"Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa","volume":"51","author":"E Mohr","year":"2018","journal-title":"Eur Respir J"},{"key":"ref382","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1124\/dmd.115.064527","article-title":"Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo","volume":"43","author":"K Sasahara","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"ref383","first-page":"332","article-title":"Toxic optic neuropathy associated with ethambutol: implications for current therapy","volume":"65","author":"P ACM Russo","year":"1994","journal-title":"J Am Optom Assoc"},{"key":"ref384","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1183\/13993003.02146-2015","article-title":"Effectiveness and safety of meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"S Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"ref385","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"S De Lorenzo","year":"2013","journal-title":"Eur Respir J"},{"key":"ref386","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijms17030373","article-title":"Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review","volume":"17","author":"G Sotgiu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref387","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1183\/13993003.00214-2016","article-title":"Comparison of effectiveness and safety of imipenem\/clavulanate- versus meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"S Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"ref388","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1183\/09031936.00188313","article-title":"Management of patients with multidrug-resistant\/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement","volume":"44","author":"C Lange","year":"2014","journal-title":"Eur Respir J"},{"key":"ref389","volume-title":"Supplement M 24 \u2013 Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes","author":"Clinical and Laboratory Standards Institute","year":"2020","edition":"3rd Edition"},{"key":"ref390","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1469-0691.2011.03551.x","article-title":"The ins and outs of Mycobacterium tuberculosis drug susceptibility testing","volume":"17","author":"E C Bottger","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref391","first-page":"703","article-title":"Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids","volume":"3","author":"C A Peloquin","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref392","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1007\/s11033-012-2433-y","article-title":"Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis","volume":"40","author":"H Du","year":"2013","journal-title":"Mol Biol Rep"},{"key":"ref393","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5588\/ijtld.11.0377","article-title":"NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis","volume":"16","author":"P Y Wang","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref394","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"J Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"ref395","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200124070-00006","article-title":"Drug treatment for tuberculosis during pregnancy: safety","volume":"24","author":"G Bothahemley","year":"2001","journal-title":"Drug Saf"},{"key":"ref396","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.17-01-00372.1997","article-title":"Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy","volume":"17","author":"M E Helgren","year":"1997","journal-title":"J Neurosci"},{"key":"ref397","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/17425255.2014.970166","article-title":"Safety issues and drug-drug interactions with commonly used quinolones","volume":"11","author":"A Douros","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref398","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"M Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"ref399","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"G Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"ref400","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"X Zhang","year":"2015","journal-title":"J Thorac Dis"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jac\/dkp171","article-title":"Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis","volume":"64","author":"W-J KO Koh","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref402","doi-asserted-by":"crossref","first-page":"e02012-19","DOI":"10.1128\/AAC.02012-19","article-title":"Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis","volume":"64","author":"A H Diacon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"ref403","doi-asserted-by":"crossref","first-page":"e00751-17","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis","volume":"61","author":"S Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"ref404","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study","volume":"77","author":"S Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"ref405","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5588\/ijtld.17.0352","article-title":"Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases","volume":"22","author":"M C Payen","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref406","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1128\/AAC.01621-06","article-title":"Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin","volume":"51","author":"M Weiner","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref407","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"H M Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref408","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"A Alsultan","year":"2014","journal-title":"Drugs"},{"key":"ref411","volume-title":"Supplement M 62 \u2013 Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes","author":"Clinical and Laboratory Standards Institute","year":"2018","edition":"1. Aufl."},{"key":"ref412","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1472-9792(08)70002-7","article-title":"Handbook of anti-tuberculosis agents. Introduction","volume":"88","author":"J PYD Brennan","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"ref413","volume-title":"Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine)","author":"World Health Organization","year":"2021"},{"key":"ref414","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis","volume":"384","author":"S E Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"ref415","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.42.7.1853","article-title":"Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis","volume":"42","author":"D L Williams","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"ref416","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"W J Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"ref417","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study","volume":"61","author":"T R Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref418","doi-asserted-by":"crossref","first-page":"e01575-17","DOI":"10.1128\/AAC.01575-17","article-title":"Role of Alanine Racemase Mutations in Mycobacterium tuberculosis d-Cycloserine Resistance","volume":"61","author":"Y Nakatani","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1934-8303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T19:52:44Z","timestamp":1728417164000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1934-8303"}},"subtitle":["Eine S2k-Leitlinie zur Diagnostik und Therapie, Chemopr\u00e4vention und Chemoprophylaxe der Tuberkulose im Erwachsenenalter des Deutschen Zentralkomitees zur Bek\u00e4mpfung der Tuberkulose e.\u200aV. (DZK) und der Deutschen Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin e.\u200aV. (DGP)"],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":387,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,16]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1934-8303","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"value":"0934-8387","type":"print"},{"value":"1438-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}